Aryl triazole-scaffold for multitarget anticancer immunomodulating drug discovery

Title : Aryl triazole-scaffold for multitarget anticancer immunomodulating drug discovery

Abstract:

A small library of aryl triazole-scaffold derivatives have been developed using click chemistry synthetic strategies. Docking studies using PD-L1 and VEGFR-2 crystallographic data confirmed their potential targeted action. The antiproliferative activity on monocultures of several tumour cell lines (HT-29, A-549 and MCF-7), and on the non-tumour cell line HEK-293 has been studied. Also, the effect on anticancer targets (PD-L1, VEGFR-2 and c-Myc) has been evaluated. Finally, the effect on cancer cell viability when co-cultured with immune cells (Jurkat T cells or THP-1) has been also studied together with their effect on IL-6 secretion to cell media.

Audience Takeaway Notes:

• The audience will learn more about multitarget anticancer drug discovery for oncoimmunomodulating therapies.
• Those people in the audience involved in Drug Discovery research could use most of the information we are going to provide.
• This is a multidisciplinary and interdisciplinary work so people from research fields involved in Medicinal Chemistry, Biochemistry, Organic Chemistry, Cell biology, Immunology could be interested.

Biography:

Dr. Eva Falomir studied Chemistry at the Valencia University, Spain and graduated as MS in 1994. She then joined the research group of Prof. Carda at Jaume I University (UJI). She received her PhD degree in 1998 at the same institution. After two years postdoctoral fellowship supervised by Dr A. Fürstner at Max-Planck Institute, Germany she obtained the position of an Associate Professor at UJI. In 2022, she got a Full Professor position in the same university. She has published more than 100 research articles in SCI(E) journals.